SAGE Therapeutics, Inc. Cash flow Statement
Figures in Million
Consolidated Cash Flow Results
Dec'24
Dec'23
Dec'22
Dec'21
Dec'20
Dec'19
No of Months
12
12
12
12
12
12
Profit Before Tax
-400.00
-541.00
-532.00
-457.00
606.00
-680.00
Adjustment
0.00
0.00
0.00
0.00
0.00
0.00
Changes In working Capital
84.00
-67.00
5.00
-18.00
-39.00
6.00
Cash Flow after changes in Working Capital
0.00
0.00
0.00
0.00
0.00
0.00
Cash Flow from Operating Activities
-267.00
-540.00
-460.00
-378.00
664.00
-528.00
Cash Flow from Investing Activities
266.00
442.00
325.00
-1,002.00
442.00
-143.00
Cash Flow from Financing Activities
10.00
6.00
3.00
13.00
426.00
607.00
Net Cash Inflow / Outflow
10.00
-91.00
-131.00
-1,367.00
1,533.00
-64.00
Opening Cash & Cash Equivalents
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
0.00
0.00
0.00
0.00
0.00
0.00
Closing Cash & Cash Equivalent
0.00
0.00
0.00
0.00
0.00
0.00
Figures in USD Million
Seasonal companies are compared with the same quarter last year
Seasonal companies are compared with the same quarter last year
Compare Cash Flow Results of SAGE Therapeutics, Inc.
Figures in Million
consolidated Cash Flow Results
Change(USD)
Change(%)
Profit Before Tax
-400.666
-144.689
-256.00
-176.92%
Adjustment
0
0
0.00
0.00%
Changes In working Capital
84.762
-1.083
85.00
7926.59%
Cash Flow after changes in Working Capital
0
0
0.00
0.00%
Cash Flow from Operating Activities
-267.194
-123.343
-144.00
-116.63%
Cash Flow from Investing Activities
266.678
14.039
252.00
1799.55%
Cash Flow from Financing Activities
10.663
257.029
-247.00
-95.85%
Net Cash Inflow / Outflow
10.147
148.799
-138.00
-93.18%
Opening Cash & Cash Equivalents
0
0
0.00
0.00%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
0
1.074
-1.00
-100.00%
Closing Cash & Cash Equivalent
0
0
0.00
0.00%
Cash Flow - Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is 50.57% vs -17.51% in Dec 2023
Dec'24
Dec'23
Change(%)
Cash Flow from Operating Activities
-267.19
-540.59
50.57%






